| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elisabeth Couture, Vanina Bongard, Jean-Christophe Maiza, Antoine Bennet, Philippe Caro. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22058008. |
to describe glucose status changes in patients with acromegaly receiving somatostatin analog lanreotide as primary treatment. |
2013-05-07 |
2023-08-12 |
Not clear |
| Carla Giordano, Alessandro Ciresi, Marco Calogero Amato, Rosario Pivonello, Renata Simona Auriemma, Ludovica Francesca Stella Grasso, Aldo Galluzzo, Annamaria Cola. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22116639. |
clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. |
2013-05-07 |
2023-08-12 |
Not clear |
| Carla Giordano, Alessandro Ciresi, Marco Calogero Amato, Rosario Pivonello, Renata Simona Auriemma, Ludovica Francesca Stella Grasso, Aldo Galluzzo, Annamaria Cola. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22116639. |
to evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. |
2013-05-07 |
2023-08-12 |
Not clear |
| Carla Giordano, Alessandro Ciresi, Marco Calogero Amato, Rosario Pivonello, Renata Simona Auriemma, Ludovica Francesca Stella Grasso, Aldo Galluzzo, Annamaria Cola. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22116639. |
two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). |
2013-05-07 |
2023-08-12 |
Not clear |
| Carla Giordano, Alessandro Ciresi, Marco Calogero Amato, Rosario Pivonello, Renata Simona Auriemma, Ludovica Francesca Stella Grasso, Aldo Galluzzo, Annamaria Cola. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22116639. |
both somatostatin analogues and surgery can safely be used as first-line therapy in acromegaly, without any untoward effects on glucose tolerance. |
2013-05-07 |
2023-08-12 |
Not clear |
| Ilan Shimon, Ariel Barka. Estrogen treatment for acromegaly. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22933045. |
we report our experience with four female patients with active acromegaly, naïve to medical treatment or inadequately controlled by somatostatin receptor ligands (srls) or the gh-receptor antagonist. |
2013-05-07 |
2023-08-12 |
Not clear |
| Anand K Annamalai, Alison Webb, Narayanan Kandasamy, Maysoon Elkhawad, Samantha Moir, Fakhar Khan, Kaisa Maki-Petaja, Emma L Gayton, Christopher H Strey, Samuel O'Toole, Shaumya Ariyaratnam, David J Halsall, Afzal N Chaudhry, Laurence Berman, Daniel J Scoffings, Nagui M Antoun, David P Dutka, Ian B Wilkinson, John M Shneerson, John D Pickard, Helen L Simpson, Mark Gurnel. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. The Journal of clinical endocrinology and metabolism. vol 98. issue 3. 2013-04-30. PMID:23393175. |
a comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. |
2013-04-30 |
2023-08-12 |
Not clear |
| Federico Gatto, Richard A Feelders, Rob van der Pas, Johan M Kros, Marlijn Waaijers, Diana Sprij-Mooij, Sebastian J C M M Neggers, Aart-Jan van der Lelij, Francesco Minuto, Steven W J Lamberts, Wouter W de Herder, Diego Ferone, Leo J Hoflan. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. The Journal of clinical endocrinology and metabolism. vol 98. issue 1. 2013-03-07. PMID:23118420. |
immunoreactivity score using an anti-sst2a receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. |
2013-03-07 |
2023-08-12 |
rabbit |
| Rajat Kumar Das, Sarmistha Banerjee, Bernard H Shapir. Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide. The Journal of endocrinology. vol 216. issue 1. 2013-03-01. PMID:23077183. |
octreotide is a potent somatostatin analog therapeutically used to treat several conditions including hyper gh secretion in patients with acromegaly. |
2013-03-01 |
2023-08-12 |
human |
| Yasemin Tutuncu, Dilek Berker, Serhat Isik, Ufuk Ozuguz, Gulhan Akbaba, Ferit Kerim Kucukler, Yusuf Aydin, Serdar Gule. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. vol 15. issue 3. 2013-02-05. PMID:21863263. |
long-acting somatostatin analogs are frequently used as adjuvant treatment of acromegaly patients after noncurative surgery. |
2013-02-05 |
2023-08-12 |
Not clear |
| Daphne T Adelman, Andrea Burgess, Philippa R Davie. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Medical devices (Auckland, N.Z.). vol 5. 2013-01-08. PMID:23293542. |
the somatostatin analogs (ssas) lanreotide autogel/depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. |
2013-01-08 |
2023-08-12 |
Not clear |
| D Ferone, F Gatto, F Minut. Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for. Journal of endocrinological investigation. vol 35. issue 6. 2012-12-07. PMID:22776973. |
pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for. |
2012-12-07 |
2023-08-12 |
Not clear |
| M Losa, V G Cripp. Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against. Journal of endocrinological investigation. vol 35. issue 6. 2012-12-07. PMID:22776974. |
pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against. |
2012-12-07 |
2023-08-12 |
Not clear |
| Rémi Marty, Stéphane Roze, Hannah Kurt. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Medical devices (Auckland, N.Z.). vol 5. 2012-11-21. PMID:23166456. |
long-acting somatostatin receptor ligands (srl) with product-specific formulation and means of administration are injected periodically in patients with acromegaly and neuroendocrine tumors. |
2012-11-21 |
2023-08-12 |
Not clear |
| Stephan Petersenn, Nicole Unger, Ke Hu, Brigitte Weisshaar, Yilong Zhang, Emmanuel Bouillaud, Karina Hermosillo Reséndiz, Yanfeng Wang, Klaus Man. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. Journal of clinical pharmacology. vol 52. issue 7. 2012-11-16. PMID:21673137. |
pasireotide is a novel multireceptor-targeted somatostatin analogue that has shown efficacy in patients with acromegaly and cushing's disease when administered by subcutaneous (sc) injection. |
2012-11-16 |
2023-08-12 |
human |
| Ludovica F S Grasso, Rosario Pivonello, Annamaria Cola. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Current opinion in endocrinology, diabetes, and obesity. vol 19. issue 4. 2012-11-02. PMID:22627686. |
somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? |
2012-11-02 |
2023-08-12 |
Not clear |
| Ludovica F S Grasso, Rosario Pivonello, Annamaria Cola. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Current opinion in endocrinology, diabetes, and obesity. vol 19. issue 4. 2012-11-02. PMID:22627686. |
to discuss the role of medical therapy of acromegaly as a first-line treatment, focusing on recent data on the use of somatostatin analogs (ssas), the first-choice pharmacotherapy for treating acromegaly. |
2012-11-02 |
2023-08-12 |
Not clear |
| b' Philippe Chanson, Peter Kamenick\\xc3\\xb. [Treatment of acromegaly: a critical analysis of the last ten years]. Annales d\'endocrinologie. vol 73. issue 2. 2012-09-14. PMID:22521857.' |
the ten previous years in terms of acromegaly treatment were essentially characterized by the experience accumulated with new formulations of somatostatin analogues or new drugs such gh-receptor antagonists recently available. |
2012-09-14 |
2023-08-12 |
Not clear |
| Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melme. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PloS one. vol 7. issue 5. 2012-09-10. PMID:22574156. |
the long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (gh) levels in patients with acromegaly and may also induce pituitary tumor shrinkage. |
2012-09-10 |
2023-08-12 |
Not clear |
| Herbert A Schmid, Chiara Lambertini, Harmke H van Vugt, Patrizia Barzaghi-Rinaudo, Judith Schäfer, Rainer Hillenbrand, Andreas W Sailer, Martina Kaufmann, Paolo Nucifor. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. vol 95. issue 3. 2012-09-04. PMID:22156600. |
activation of somatostatin receptors (sstr1-5) by somatostatin and its analogues exerts an inhibitory effect on hormone secretion and provides the basis for the treatment of a range of endocrine diseases such as acromegaly, cushing's disease and neuroendocrine tumors (net). |
2012-09-04 |
2023-08-12 |
human |